ASCO insights: Bria-IMT + checkpoint inhibitor trials in metastatic breast cancer

Written by Carmen Calfa (Sylvester Comprehensive Cancer Center; FL; USA)
ASCO 2025 Breast Clinical trials Events coverage Opinion

We recently caught up with Carmen Calfa (Sylvester Comprehensive Cancer Center, FL, USA) to discuss her poster presentation at ASCO 2025, which highlighted survival results for Bria-IMT + checkpoint inhibitors for metastatic breast cancer (MBC) patients. In this interview, Calfa shares key takeaways from her research, discusses the impact of HLA matching on clinical outcomes’ and offers valuable advice for breast cancer oncologists attending the ASCO Annual Meeting for the first time. What are the key takeaways from your ASCO poster presentation on Bria-IMT + checkpoint inhibitor for MBC? The Bria-IMT regimen, which is a combination immunotherapy consisting of allogeneic whole cell...

To view this content, please register now for access

It's completely free